Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trabedersen,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Cromos Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OT-101, is a first-in-class anti-TGF-β2 RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer (metastatic pancreatic cancer) patients. TGF-β2 has been implicated as a key contributor to the immunosuppressive landscape ...
Brand Name : OT-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 23, 2023
Lead Product(s) : Trabedersen,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Cromos Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?